Wet Age-Related Macular Degeneration Market to Reach USD 18.4 Billion by 2032 | CAGR 7.8%
Author : KUMUD SINGH | Published On : 23 Mar 2026
According to a newly published market research report by 24LifeSciences, global Wet Age-Related Macular Degeneration (AMD) market was valued at USD 9.6 billion in 2024 and is projected to reach USD 18.4 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period 2025-2032.
Wet AMD, the advanced form of age-related macular degeneration, is characterized by abnormal blood vessel growth under the retina leading to rapid central vision loss. While accounting for only 10-15% of all AMD cases, it's responsible for 90% of severe vision loss associated with the condition. The market's growth is primarily driven by the increasing global elderly population, with over 80% of AMD cases occurring in individuals aged 60+.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/15671/wet-age-related-macular-degeneration-amd-market
Aging Population and Disease Prevalence Drive Market Expansion
The rapid growth of the geriatric population globally remains the primary driver for the wet AMD market. Approximately 8.7% of the global population aged 55+ is affected by AMD, creating a substantial patient pool requiring treatment. While developed regions currently lead in treatment adoption, emerging economies are witnessing accelerated market growth due to improving healthcare infrastructure and increased awareness.
Recent therapeutic advancements, particularly in anti-VEGF therapies and gene treatments, have significantly improved outcomes for wet AMD patients. The introduction of longer-acting formulations and improved drug delivery systems has enhanced treatment efficacy while reducing the burden of frequent injections.
Technological Advancements in Treatment Modalities
The wet AMD treatment landscape has been revolutionized by anti-VEGF therapies like aflibercept and ranibizumab, which inhibit abnormal blood vessel growth. Recent developments have focused on extended-duration formulations that reduce treatment frequency from monthly to every 12-16 weeks, dramatically improving patient compliance and quality of life.
Gene therapies and sustained-release drug delivery systems represent the next frontier in wet AMD treatment, with several candidates in late-stage clinical trials. These innovations promise to transform the treatment paradigm from chronic management to potential one-time therapies.
Market Challenges: Cost Barriers and Treatment Accessibility
Despite its growth potential, the wet AMD market faces significant challenges:
-
High treatment costs - Anti-VEGF therapies cost approximately $2,000 per injection
-
Limited access in developing regions - Only 30-40% of eligible patients receive standard care in some markets
-
Patient compliance issues - Dropout rates approach 25% after two years due to treatment burden
-
Variable response rates - 20-30% of patients show suboptimal response to existing therapies
The upcoming patent expirations of major anti-VEGF drugs may introduce price competition but could also improve treatment accessibility in cost-sensitive markets.
Get the Complete Report & Table of Contents: https://www.24lifesciences.com/wet-age-related-macular-degeneration-amd-market-15671
North America Dominates While Asia-Pacific Shows Rapid Growth
The North American region currently leads the global wet AMD market, supported by advanced healthcare infrastructure, favorable reimbursement policies, and high adoption of premium therapies. However, the Asia-Pacific region is emerging as the fastest-growing market, driven by improving healthcare systems and increasing diagnosis rates in countries like China and India.
Key factors influencing regional market dynamics include:
-
Variations in healthcare reimbursement systems
-
Differences in treatment protocols and accessibility
-
Regional prevalence of AMD and aging populations
-
Adoption rates of innovative therapies
Europe maintains a strong position as the second-largest market, while other regions show varied growth patterns based on economic and healthcare factors.
Anti-VEGF Therapies Lead Treatment Approaches
By treatment type, anti-VEGF therapies dominate the market due to their proven efficacy in slowing disease progression and preserving vision. These injectable therapies have become the gold standard, though their market position faces potential disruption from emerging gene therapies and sustained-release formulations currently in development.
The hospital segment represents the largest application area, as wet AMD treatment typically requires specialized equipment and professional administration. However, telemedicine platforms for AMD monitoring are expanding rapidly, potentially changing traditional treatment patterns.
Competitive Landscape: Established Players and Emerging Innovators
The global wet AMD market features a mix of established pharmaceutical giants and innovative biotech firms. The market is moderately concentrated, with the top three players accounting for approximately 60% of the global market share.
Key companies profiled in the report include:
-
Novartis International
-
F. Hoffmann-La Roche
-
Regeneron Pharmaceuticals
-
Bayer
-
Allergan
-
Adverum Biotechnologies
-
Neurotech Pharmaceuticals
-
and More
The competitive environment is shaped by factors including treatment efficacy, dosing frequency, pricing strategies, and geographic coverage, with innovation serving as a key differentiator.
Market Opportunities: Emerging Therapies and Global Expansion
Significant growth opportunities exist in several areas:
-
Gene therapies currently in development could capture 15-20% of the market within five years of approval
-
Emerging markets present untapped potential as healthcare infrastructure improves
-
AI-assisted diagnostics with 94% accuracy in clinical trials could significantly increase treatment-eligible patient identification
-
Biosimilars offer cost-saving opportunities as major drugs go off-patent
Companies are increasingly focusing on developing treatments with improved efficacy, extended duration, and reduced administration frequency to address current market limitations.
Access the Full Report
Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/15671/wet-age-related-macular-degeneration-amd-market
Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/wet-age-related-macular-degeneration-amd-market-15671
About 24LifeSciences
24LifeSciences is a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.
